A SYSTEMATIC REVIEW OF NURSES’ AND DOCTOR’S KNOWLEDGE, ATTITUDES, AND PRACTICE IN CONNECTION TO PHARMACOVIGILANCE AND ADVERSE DRUG REACTION REPORTING
Main Article Content
Keywords
.
Abstract
Objective: This study aims to explore aspects of pharmacovigilance and adverse drug reaction (ADR) reporting, including knowledge, attitudes, practice, and perceived barriers from a nurse perspective. Methodology: A systematic review was conducted by searching electronic databases such as MEDLINE, Embase Scopus and Web of Knowledge between January 2010 to October 2020. Original observational studies focusing on Nurses’ and Doctor’s understanding about pharmacovigilance activities in different healthcare settings were included if they written in English language. Results: From the search process carried out during this period we identified twenty-three qualifying studies that met our inclusion criteria. Findings revealed that while as many as 74.1% of nurses had an awareness regarding definitions related to ADRs only one quarter knew how to fill up an adverse drug reaction reporting form accurately. Further analysis showed most (84%) believe it is important for patient/medicine safety but reportage remained low at just over one-fifth because lack education/training barrier which stood around median percentage value amounting close-to half among all surveyed respondents emerged repeatedly across multiple variables studied here - appropriateness expanding such education interventions through enhancing degree-level courses ought help address these obstacles hampering routine involvement with adequate standardisation measures required ensuring better compliance rates overall especially amongst nursing cohorts globally." Conclusion: Despite favorable attitude towards ADER , there exist considerable gaps within obtained results owing various factors contributing them; thus developing requisite skillsets along training programs extending beyond basic clinical guidelines could be beneficial strategies supporting vigilante scientist endeavours geared achieving improved tracking communicate feedback loop susceptible populations exposed drugs monitored systematically enabling timely response prevent cause lasting harm overall health infrastructure systems alike taken cognizant imperative stakeholder interests involved ultimately yielding positive gains everyone aerospace .
References
1. Adverse Drug Reaction Reporting, Lee B. Murdaugh, RPh, PhD 1972.
2. Muaed Jamal Alomar, “Factors affecting the development of adverse drug reactions (Review article),” National Library of Medicine., 2014.
3. Rostam Osanlou, Lauren Walker, Dyfrig A Hughes, Girvan Burnside, and Munir “Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions” National Library of Medicine., 2022.
4. Jesús Ruiz-Ramos., “Drug-Related Problems in Elderly Patients Attended to by Emergency Services,” Journal of Clinical Medicine., 2023.
5. G. Baker, P. Norton, V. Flintoft et al., “The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada,” Canadian Medical Association Journal., vol. 170, no. 11, pp. 1678–1686, 2004.
6. C. Kongkaew, P. R. Noyce, and D. M. Ashcroft, “Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies,” Annals of Pharmacotherapy., vol. 42, no. 7-8, pp. 1017–1025, 2008.
7. https://www.aha.org/costsofcaring, “The Financial Stability of America’s Hospitals and Health Systems Is at Risk as the Costs of Caring Continue to Rise,” April 2023.
8. M. A. Hadi, C. F. Neoh, R. M. Zin, M. E. Elrggal, and
9. E. Cheema, “Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting,” Integrated pharmacy research & practice., vol. Volume 6, pp. 91–98, 2017.
10. M. D. Rawlins, “Pharmacovigilance: paradise lost, regained or postponed?: the William withering lecture 1994,” Journal of the Royal College of Physicians of London., vol. 29, no. 1, pp. 41–49, 1995.
11. M. Suyagh, D. Farah, and R. A. Farha, “Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process,” Saudi Pharmaceutical Journal, vol. 23, no. 2, pp. 147–153, 2015.
12. J. Lexchin, “Is there still a role for spontaneous reporting of adverse drug reactions?,” Canadian Medical Association Journal., vol. 174, no. 2, pp. 191-192, 2006.
13. J. Sultana, P. Cutroneo, and G. Trifirò, “Clinical and economic burden of adverse drug reactions,” Journal of pharmacology & pharmacotherapeutics., vol. 4, Suppl 1, pp. S73–S77, 2013.
14. T. T. le, T. T. H. Nguyen, C. Nguyen et al., “Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam,” Journal of Clinical Pharmacy and Therapeutics., vol. 45, no. 1, pp. 122–127, 2020.
15. A. De Angelis, A. Giusti, S. Colaceci, E. Vellone, and R. Alvaro, “Nurses’ and Doctor’s reporting of suspect adverse drug reactions: a mixedmethods study,” Annali dell'Istituto superiore di sanita., vol. 51, no. 4, pp. 277–283, 2015.
16. H. H. Ampadu, J. Hoekman, M. L. de Bruin et al., “Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®,” Drug Safety, vol. 39, no. 4, pp. 335–345, 2016.
17. Danae F. Sfantou, “Importance of Leadership Style towards Quality of Care Measures in Healthcare Settings: A Systematic Review” National Library of Medicine 2017 Dec; 5(4): 73.
18. Greta G. Cummings, “The essentials of nursing leadership: A systematic review of factors and educational interventions influencing nursing leadership,” International Journal of Nursing Studies, 2013.
19. T. Schutte, R. van Eekeren, M. Richir et al., “The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study,” Naunyn-Schmiedeberg's archives of pharmacology., vol. 391, no. 1, pp. 17–26, 2018.
20. A. D. Angelis, L. Pancani, P. Steca et al., “Testing an explanatory model of Nurses’ and Doctor’s intention to report adverse drug reactions in hospital settings,” Journal of Nursing Management., vol. 25, no. 4, pp. 307–317, 2017.
21. N. Haider and F. Mazhar, “Factors associated with underreporting of adverse drug reactions by nurses: a narrative literature review,” Saudi Journal for Health Sciences., vol. 6, no. 2, p. 71, 2017.
22. Nadia Hachoumi “Health sciences lifelong learning and professional development in the era of artificial intelligence,”
23. International Journal of Medical Informatics., Volume 178, October 2023.
24. D. Mendes, C. Alves, and M. F. Batel, “Nurses’ and Doctor’s spontaneous reporting of adverse drug reactions: expert review of routine reports,” Journal of Nursing Management, vol. 22, no. 3, pp. 322–330, 2014.
25. S. K. Gupta, R. P. Nayak, R. Shivaranjani, and S. K. Vidyarthi, “A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India,” Perspectives in clinical research, vol. 6, no. 1, pp. 45–52, 2015.
26. E. Aromataris and A. Pearson, “The systematic review,” The American Journal of Nursing, vol. 114, no. 3, pp. 53–58, 2014.
27. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Journal of clinical epidemiology, vol. 62, no. 10, pp. e1–e34, 2009.
28. “Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies,” 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034723/. 2007 Oct 20.
29. S. Hawker, S. Payne, C. Kerr, M. Hardey, and J. Powell, “Appraising the evidence: reviewing disparate data systematically,” Qualitative health research, vol. 12, no. 9, pp. 1284– 1299, 2002.
30. A. Bepari, S. K. Niazi, I. Rahman, and A. M. Dervesh, “The comparative evaluation of knowledge, attitude, and practice of different health-care professionals about the pharmacovigilance system of India,” Journal of Advanced Pharmaceutical Technology & Research., vol. 10, no. 2, pp. 68–74, 2019.
31. S. Ganesan, G. Vikneswaran, K. C. Reddy, D. Subrahmanyam, and C. Adithan, “A survey on knowledge, attitude and practice of pharmacovigilance towards adverse drug reactions reporting among doctors and nurses in a tertiary care hospital in South India,” Journal of Young Pharmacists, vol. 8, no. 4, pp. 471–476, 2016.
32. R. Rajalakshmi, B. V. Devi, T. Prasad, S. Swetha, and B. Dharini, “Knowledge, attitude and practice towards pharmacovigilance and adverse drug reaction reporting among nurses in a tertiary care hospital, Tirupati,” International Journal of Pharmaceutical and Clinical Research, vol. 9, no. 11, pp. 683–689, 2017.
33. R Rajalakshmi, “Knowledge, Attitude and Practice Towards Pharmacovigilance and Adverse Drug Reaction Reporting Among Doctors' in A Tertiary Care Hospital, Tirupati,” Indian journal of pharmacology, November 2017, https://www.researchgate.net/
34. S. Bogolubova, N. Padayachee, and N. Schellack, “Knowledge, attitudes and practices of nurses and pharmacists towards adverse drug reaction reporting in the South African private hospital sector,” Health SA Gesondheid: Journal of Interdisciplinary Health Sciences, vol. 23, pp. 1–9, 2018.
35. Y. Gordhon and N. Padayachee, “Evaluating the knowledge, attitudes and practices of healthcare workers towards adverse drug reaction reporting at a public tertiary hospital in Johannesburg,” International Journal of Africa Nursing Sciences, vol. 12, article 100191, 2020.
36. A. Terblanche, J. C. Meyer, B. Godman, and R. S. Summers, “Knowledge, attitudes and perspective on adverse drug reaction reporting in a public sector hospital in South Africa: baseline analysis,” Hospital practice., vol. 45, no. 5, pp. 238–245, 2017.
37. Y. Ergün, T. B. Ergün, E. Toker, E. Ünal, and M. Akben, “Knowledge attitude and practice of Turkish health professionals towards pharmacovigilance in a university hospital,” International health., vol. 11, no. 3, pp. 177–184, 2019.
38. M. D. Güner and P. E. Ekmekci, “Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates,” Journal of drug assessment., vol. 8, no. 1, pp. 13–20, 2019.
39. F. Vural, S. Çiftçi, and B. Vural, “The knowledge, attitude and behaviours of nurses about pharmacovigilance, adverse drug reaction and adverse event reporting in a state hospital,” Northern clinics of Istanbul, vol. 1, no. 3, pp. 147–152, 2014.
40. M. M. Abdel-Latif and B. A. Abdel-Wahab, “Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah AlMunawwarah, Kingdom of Saudi Arabia,” Saudi pharmaceutical journal, vol. 23, no. 2, pp. 154–161, 2015.
41. T. M. AlShammari and M. J. Almoslem, “Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: a multicentre cross sectional study,” Saudi pharmaceutical journal, vol. 26, no. 7, pp. 925–931, 2018.
42. K. Abu Hammour, F. El-Dahiyat, and F. R. Abu, “Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan,” Journal of Evaluation in Clinical Practice, vol. 23, no. 3, pp. 608–613, 2017.
43. A. A. Al Rabayah, E. M. Hanoun, and R. H. Al Rumman,
44. “Assessing knowledge, attitude, and practices of health-care providers toward pharmacovigilance and adverse drug reaction reporting at a comprehensive cancer center in Jordan,” Perspectives in Clinical Research, vol. 10, no. 3, pp. 115–120, 2019.
45. A. Ahmed, M. Yousuf, A. A. Nisar-Ur-RAHMAN, A. Ayaz, K. UNAR, and M. RIZWAN, “Evaluations of adverse drug reaction reporting among healthcare professionals in a tertiary care hospital at north part of Sindh Pakistan,” Latin American Journal of Pharmacy, vol. 36, no. 1, pp. 37–43, 2017.
46. S. Shamim, S. M. Sharib, S. M. Malhi et al., “Adverse drug reactions (ADRS) reporting: awareness and reasons of underreporting among health care professionals, a challenge for pharmacists,” Springer Plus, vol. 5, no. 1, p. 1778, 2016.
47. K. Danekhu, S. Shrestha, S. Aryal, and P. R. Shankar, Healthcare professionals’ knowledge and perception of adverse drug reaction reporting and pharmacovigilance in a tertiary care teaching hospital of Nepal, Hospital Pharmacy, 2019.
48. K. Santosh, P. Tragulpiankit, I. R. Edwards, and S. Gorsanan, “Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal,” International journal of risk & safety in medicine, vol. 25, no. 1, pp. 1–16, 2013.
49. C. Dorji, P. Tragulpiankit, A. Riewpaiboon, and T. Tobgay, “Knowledge of adverse drug reaction reporting among healthcare professionals in Bhutan: a cross-sectional survey,” Drug safety., vol. 39, no. 12, pp. 1239–1250, 2016.
50. E. Ekman, G. Petersson, S. Tågerud, and M. Bäckström, “Awareness among nurses about reporting of adverse drug reactions in Sweden,” Drug, Healthcare and Patient Safety, vol. 4, pp. 61–66, 2012.
51. S. Hanafi, H. Torkamandi, A. Hayatshahi, K. Gholami, and M. Javadi, “Knowledge, attitudes and practice of nurse regarding adverse drug reaction reporting,” Iranian journal of nursing and midwifery research., vol. 17, no. 1, pp. 21–25, 2012.
52. L. J. John, M. Arifulla, J. J. Cheriathu, and J. Sreedharan, “Reporting of adverse drug reactions: an exploratory study among nurses in a teaching hospital, Ajman, United Arab Emirates,” DARU: Journal of Pharmaceutical Sciences., vol. 20, no. 1, p. 44, 2012.
53. H. Shanko and J. Abdela, “Knowledge, attitudes, and practices of health care professionals toward adverse drug reaction reporting in Hiwot Fana Specialized University Hospital, Harar, eastern Ethiopia: a cross-sectional study,” Hospital Pharmacy, vol. 53, no. 3, pp. 177–187, 2018.
54. S. A. Khan, C. Goyal, N. Chandel, and M. Rafi, “Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study,” Journal of Natural Science, Biology, and Medicine, vol. 4, no. 1, pp. 191–196, 2013.
55. A. Vallano, G. Cereza, C. Pedròs et al., “Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital,” British journal of clinical pharmacology., vol. 60, no. 6, pp. 653–658, 2005.
56. A. S. Bhagavathula, A. A. Elnour, S. Q. Jamshed, and A. Shehab, “Health professionals' knowledge, attitudes and practices about pharmacovigilance in India: a systematic review and meta-analysis,” Plo S one, vol. 11, no. 3, article e0152221, 2016.
57. A. D. Hailu and S. A. Mohammed, “Adverse drug reaction reporting in Ethiopia: systematic review,” Bio Med Research International, vol. 2020, article 8569314, pp. 1–12, 2020.
58. Morrison Asiamah, “Spontaneous reporting of adverse drug reaction among health professionals in Ghana”, Pub Med Central ., Published online 2022 Jan 20.
59. S. Palaian, M. I. Ibrahim, and P. Mishra, “Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal,” Pharmacy practice, vol. 9, no. 4, pp. 228–235, 2011.
60. E. Hristov, S. Ognyanov, T. Deliyski et al., “Effect of pharmacist involvement on patient reporting of adverse drug reactions in Bulgaria,” Journal of Advanced Research in Pharmaceutical Sciences and Pharmacology Interventions, vol. 2, no. 2, pp. 1– 6, 2019.
61. H. Rehan, R. K. Sah, and D. Chopra, “Comparison of knowledge, attitude and practices of resident doctors and nurses on adverse drug reaction monitoring and reporting in a tertiary
62. care hospital,” Indian journal of pharmacology., vol. 44, no. 6, pp. 699–703, 2012.
63. J. Liu, Z. Zhou, S. Yang et al., “Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China,” International Journal of Clinical Pharmacy, vol. 37, no. 3, pp. 457–464, 2015.
64. S. Gautron, J. Wentzell, S. Kanji, T. Nguyen, D. Kobewka, and D. E. Mac, “Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting,” The Canadian journal of hospital pharmacy, vol. 71, no. 5, pp. 316–323, 2018.
65. A. De Angelis, S. Colaceci, A. Giusti, E. Vellone, and R. Alvaro, “Factors that condition the spontaneous reporting of adverse drug reactions among nurses: an integrative review,” Journal of nursing management., vol. 24, no. 2, pp. 151–163, 2016.
66. A. R. Abubakar, N. B. Simbak, and M. Haque, “A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors,” Journal of Applied Pharmaceutical Science., vol. 4, no. 10, pp. 117–127, 2014.
67. M. Vaismoradi, S. Jordan, and M. Kangasniemi, “Patient participation in patient safety and nursing input–a systematic review,” Journal of clinical nursing., vol. 24, no. 5-6, pp. 627– 639, 2015.
68. F. R. Varallo, S. O. P. Guimarães, S. A. R. Abjaude, and P. C. Mastroianni, “Causes for the underreporting of adverse drug events by health professionals: a systematic review,” Revista da Escola de Enfermagem da USP, vol. 48, no. 4, pp. 739–747, 2014.
69. T. Dilles, R. V. Stichele, B. Van Rompaey, L. Van Bortel, and M. Elseviers, “Nurses’ and Doctor’s practices in pharmacotherapy and their association with educational level,” Journal of advanced nursing., vol. 66, no. 5, pp. 1072–1079, 2010.
70. G. Cereza, A. Agustí, C. Pedrós et al., “Effect of an intervention on the features of adverse drug reactions spontaneously reported in a hospital,” European journal of clinical pharmacology., vol. 66, no. 9, pp. 937–945, 2010.
71. D. Stewart, K. Mac Lure, V. Paudyal, C. Hughes, M. Courtenay, and J. McLay, “Non-medical prescribers and pharmacovigilance: participation, competence and future needs,” International Journal of Clinical Pharmacy, vol. 35, no. 2, pp. 268–274, 2013.
72. M. Bäckström, E. Ekman, and T. Mjörndal, “Adverse drug reaction reporting by nurses in Sweden,” European journal of clinical pharmacology., vol. 63, no. 6, pp. 613–618, 2007.
73. M. E. Ndosi and R. Newell, “Nurses’ and Doctor’s knowledge of pharmacology behind drugs they commonly administer,” Journal of clinical nursing., vol. 18, no. 4, pp. 570–580, 2009.
74. M. Vaismoradi, S. Jordan, F. Vizcaya-Moreno, I. Friedl, and M. Glarcher, “PRN medicines optimization and nurse education,” Pharmacy., vol. 8, no. 4, p. 201, 2020.
75. A. Mardani, P. Griffiths, and M. Vaismoradi, “The role of the nurse in the management of medicines during transitional care: a systematic review,” Journal of multidisciplinary healthcare, vol. Volume 13, pp. 1347–1361, 2020.
76. Lavina Prashar, “Inadequate Knowledge and Practice of Pharmacovigilance affecting Adverse Drug Reaction Reporting by Health Professionals in Private Healthcare Facilities in Lusaka, Zambia,” ResearchGate, March 2020
77. C. K. Desai, G. Iyer, J. Panchal, S. Shah, and R. Dikshit, “An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital,” Perspectives in Clinical research, vol. 2, no. 4, pp. 129–136, 2011.
78. M. Bisht, S. Singh, and D. Dhasmana, “Effect of educational intervention on adverse drug reporting by physicians: a cross-sectional study,” International Scholarly Research Notices., vol. 2014, article 259476, pp. 1–8, 2014.
79. L. Hazell and S. A. Shakir, “Under-reporting of adverse drug reactions,” Drug safety, vol. 29, no. 5, pp. 385–396, 2006.
80. E. Lopez-Gonzalez, M. T. Herdeiro, and A. Figueiras, “Determinants of under-reporting of adverse drug reactions,” Drug safety., vol. 32, no. 1, pp. 19–31, 2009.
81. C. Palleria, C. Leporini, S. Chimirri et al., “Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two “challenging” case reports,” Journal of pharmacology & pharmacotherapeutics., vol. 4, Suppl 1, pp. S66–S72, 2013.
82. Dorkasi L. Mwakawanga, “Pharmacovigilance and Adverse Drug Reactions Reporting: Healthcare Providers' Experiences from Southern Highland Tanzania,” Adv Pharmacol Pharm Sci. 2023.
2. Muaed Jamal Alomar, “Factors affecting the development of adverse drug reactions (Review article),” National Library of Medicine., 2014.
3. Rostam Osanlou, Lauren Walker, Dyfrig A Hughes, Girvan Burnside, and Munir “Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions” National Library of Medicine., 2022.
4. Jesús Ruiz-Ramos., “Drug-Related Problems in Elderly Patients Attended to by Emergency Services,” Journal of Clinical Medicine., 2023.
5. G. Baker, P. Norton, V. Flintoft et al., “The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada,” Canadian Medical Association Journal., vol. 170, no. 11, pp. 1678–1686, 2004.
6. C. Kongkaew, P. R. Noyce, and D. M. Ashcroft, “Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies,” Annals of Pharmacotherapy., vol. 42, no. 7-8, pp. 1017–1025, 2008.
7. https://www.aha.org/costsofcaring, “The Financial Stability of America’s Hospitals and Health Systems Is at Risk as the Costs of Caring Continue to Rise,” April 2023.
8. M. A. Hadi, C. F. Neoh, R. M. Zin, M. E. Elrggal, and
9. E. Cheema, “Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting,” Integrated pharmacy research & practice., vol. Volume 6, pp. 91–98, 2017.
10. M. D. Rawlins, “Pharmacovigilance: paradise lost, regained or postponed?: the William withering lecture 1994,” Journal of the Royal College of Physicians of London., vol. 29, no. 1, pp. 41–49, 1995.
11. M. Suyagh, D. Farah, and R. A. Farha, “Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process,” Saudi Pharmaceutical Journal, vol. 23, no. 2, pp. 147–153, 2015.
12. J. Lexchin, “Is there still a role for spontaneous reporting of adverse drug reactions?,” Canadian Medical Association Journal., vol. 174, no. 2, pp. 191-192, 2006.
13. J. Sultana, P. Cutroneo, and G. Trifirò, “Clinical and economic burden of adverse drug reactions,” Journal of pharmacology & pharmacotherapeutics., vol. 4, Suppl 1, pp. S73–S77, 2013.
14. T. T. le, T. T. H. Nguyen, C. Nguyen et al., “Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam,” Journal of Clinical Pharmacy and Therapeutics., vol. 45, no. 1, pp. 122–127, 2020.
15. A. De Angelis, A. Giusti, S. Colaceci, E. Vellone, and R. Alvaro, “Nurses’ and Doctor’s reporting of suspect adverse drug reactions: a mixedmethods study,” Annali dell'Istituto superiore di sanita., vol. 51, no. 4, pp. 277–283, 2015.
16. H. H. Ampadu, J. Hoekman, M. L. de Bruin et al., “Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®,” Drug Safety, vol. 39, no. 4, pp. 335–345, 2016.
17. Danae F. Sfantou, “Importance of Leadership Style towards Quality of Care Measures in Healthcare Settings: A Systematic Review” National Library of Medicine 2017 Dec; 5(4): 73.
18. Greta G. Cummings, “The essentials of nursing leadership: A systematic review of factors and educational interventions influencing nursing leadership,” International Journal of Nursing Studies, 2013.
19. T. Schutte, R. van Eekeren, M. Richir et al., “The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study,” Naunyn-Schmiedeberg's archives of pharmacology., vol. 391, no. 1, pp. 17–26, 2018.
20. A. D. Angelis, L. Pancani, P. Steca et al., “Testing an explanatory model of Nurses’ and Doctor’s intention to report adverse drug reactions in hospital settings,” Journal of Nursing Management., vol. 25, no. 4, pp. 307–317, 2017.
21. N. Haider and F. Mazhar, “Factors associated with underreporting of adverse drug reactions by nurses: a narrative literature review,” Saudi Journal for Health Sciences., vol. 6, no. 2, p. 71, 2017.
22. Nadia Hachoumi “Health sciences lifelong learning and professional development in the era of artificial intelligence,”
23. International Journal of Medical Informatics., Volume 178, October 2023.
24. D. Mendes, C. Alves, and M. F. Batel, “Nurses’ and Doctor’s spontaneous reporting of adverse drug reactions: expert review of routine reports,” Journal of Nursing Management, vol. 22, no. 3, pp. 322–330, 2014.
25. S. K. Gupta, R. P. Nayak, R. Shivaranjani, and S. K. Vidyarthi, “A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India,” Perspectives in clinical research, vol. 6, no. 1, pp. 45–52, 2015.
26. E. Aromataris and A. Pearson, “The systematic review,” The American Journal of Nursing, vol. 114, no. 3, pp. 53–58, 2014.
27. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Journal of clinical epidemiology, vol. 62, no. 10, pp. e1–e34, 2009.
28. “Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies,” 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034723/. 2007 Oct 20.
29. S. Hawker, S. Payne, C. Kerr, M. Hardey, and J. Powell, “Appraising the evidence: reviewing disparate data systematically,” Qualitative health research, vol. 12, no. 9, pp. 1284– 1299, 2002.
30. A. Bepari, S. K. Niazi, I. Rahman, and A. M. Dervesh, “The comparative evaluation of knowledge, attitude, and practice of different health-care professionals about the pharmacovigilance system of India,” Journal of Advanced Pharmaceutical Technology & Research., vol. 10, no. 2, pp. 68–74, 2019.
31. S. Ganesan, G. Vikneswaran, K. C. Reddy, D. Subrahmanyam, and C. Adithan, “A survey on knowledge, attitude and practice of pharmacovigilance towards adverse drug reactions reporting among doctors and nurses in a tertiary care hospital in South India,” Journal of Young Pharmacists, vol. 8, no. 4, pp. 471–476, 2016.
32. R. Rajalakshmi, B. V. Devi, T. Prasad, S. Swetha, and B. Dharini, “Knowledge, attitude and practice towards pharmacovigilance and adverse drug reaction reporting among nurses in a tertiary care hospital, Tirupati,” International Journal of Pharmaceutical and Clinical Research, vol. 9, no. 11, pp. 683–689, 2017.
33. R Rajalakshmi, “Knowledge, Attitude and Practice Towards Pharmacovigilance and Adverse Drug Reaction Reporting Among Doctors' in A Tertiary Care Hospital, Tirupati,” Indian journal of pharmacology, November 2017, https://www.researchgate.net/
34. S. Bogolubova, N. Padayachee, and N. Schellack, “Knowledge, attitudes and practices of nurses and pharmacists towards adverse drug reaction reporting in the South African private hospital sector,” Health SA Gesondheid: Journal of Interdisciplinary Health Sciences, vol. 23, pp. 1–9, 2018.
35. Y. Gordhon and N. Padayachee, “Evaluating the knowledge, attitudes and practices of healthcare workers towards adverse drug reaction reporting at a public tertiary hospital in Johannesburg,” International Journal of Africa Nursing Sciences, vol. 12, article 100191, 2020.
36. A. Terblanche, J. C. Meyer, B. Godman, and R. S. Summers, “Knowledge, attitudes and perspective on adverse drug reaction reporting in a public sector hospital in South Africa: baseline analysis,” Hospital practice., vol. 45, no. 5, pp. 238–245, 2017.
37. Y. Ergün, T. B. Ergün, E. Toker, E. Ünal, and M. Akben, “Knowledge attitude and practice of Turkish health professionals towards pharmacovigilance in a university hospital,” International health., vol. 11, no. 3, pp. 177–184, 2019.
38. M. D. Güner and P. E. Ekmekci, “Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates,” Journal of drug assessment., vol. 8, no. 1, pp. 13–20, 2019.
39. F. Vural, S. Çiftçi, and B. Vural, “The knowledge, attitude and behaviours of nurses about pharmacovigilance, adverse drug reaction and adverse event reporting in a state hospital,” Northern clinics of Istanbul, vol. 1, no. 3, pp. 147–152, 2014.
40. M. M. Abdel-Latif and B. A. Abdel-Wahab, “Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah AlMunawwarah, Kingdom of Saudi Arabia,” Saudi pharmaceutical journal, vol. 23, no. 2, pp. 154–161, 2015.
41. T. M. AlShammari and M. J. Almoslem, “Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: a multicentre cross sectional study,” Saudi pharmaceutical journal, vol. 26, no. 7, pp. 925–931, 2018.
42. K. Abu Hammour, F. El-Dahiyat, and F. R. Abu, “Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan,” Journal of Evaluation in Clinical Practice, vol. 23, no. 3, pp. 608–613, 2017.
43. A. A. Al Rabayah, E. M. Hanoun, and R. H. Al Rumman,
44. “Assessing knowledge, attitude, and practices of health-care providers toward pharmacovigilance and adverse drug reaction reporting at a comprehensive cancer center in Jordan,” Perspectives in Clinical Research, vol. 10, no. 3, pp. 115–120, 2019.
45. A. Ahmed, M. Yousuf, A. A. Nisar-Ur-RAHMAN, A. Ayaz, K. UNAR, and M. RIZWAN, “Evaluations of adverse drug reaction reporting among healthcare professionals in a tertiary care hospital at north part of Sindh Pakistan,” Latin American Journal of Pharmacy, vol. 36, no. 1, pp. 37–43, 2017.
46. S. Shamim, S. M. Sharib, S. M. Malhi et al., “Adverse drug reactions (ADRS) reporting: awareness and reasons of underreporting among health care professionals, a challenge for pharmacists,” Springer Plus, vol. 5, no. 1, p. 1778, 2016.
47. K. Danekhu, S. Shrestha, S. Aryal, and P. R. Shankar, Healthcare professionals’ knowledge and perception of adverse drug reaction reporting and pharmacovigilance in a tertiary care teaching hospital of Nepal, Hospital Pharmacy, 2019.
48. K. Santosh, P. Tragulpiankit, I. R. Edwards, and S. Gorsanan, “Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal,” International journal of risk & safety in medicine, vol. 25, no. 1, pp. 1–16, 2013.
49. C. Dorji, P. Tragulpiankit, A. Riewpaiboon, and T. Tobgay, “Knowledge of adverse drug reaction reporting among healthcare professionals in Bhutan: a cross-sectional survey,” Drug safety., vol. 39, no. 12, pp. 1239–1250, 2016.
50. E. Ekman, G. Petersson, S. Tågerud, and M. Bäckström, “Awareness among nurses about reporting of adverse drug reactions in Sweden,” Drug, Healthcare and Patient Safety, vol. 4, pp. 61–66, 2012.
51. S. Hanafi, H. Torkamandi, A. Hayatshahi, K. Gholami, and M. Javadi, “Knowledge, attitudes and practice of nurse regarding adverse drug reaction reporting,” Iranian journal of nursing and midwifery research., vol. 17, no. 1, pp. 21–25, 2012.
52. L. J. John, M. Arifulla, J. J. Cheriathu, and J. Sreedharan, “Reporting of adverse drug reactions: an exploratory study among nurses in a teaching hospital, Ajman, United Arab Emirates,” DARU: Journal of Pharmaceutical Sciences., vol. 20, no. 1, p. 44, 2012.
53. H. Shanko and J. Abdela, “Knowledge, attitudes, and practices of health care professionals toward adverse drug reaction reporting in Hiwot Fana Specialized University Hospital, Harar, eastern Ethiopia: a cross-sectional study,” Hospital Pharmacy, vol. 53, no. 3, pp. 177–187, 2018.
54. S. A. Khan, C. Goyal, N. Chandel, and M. Rafi, “Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study,” Journal of Natural Science, Biology, and Medicine, vol. 4, no. 1, pp. 191–196, 2013.
55. A. Vallano, G. Cereza, C. Pedròs et al., “Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital,” British journal of clinical pharmacology., vol. 60, no. 6, pp. 653–658, 2005.
56. A. S. Bhagavathula, A. A. Elnour, S. Q. Jamshed, and A. Shehab, “Health professionals' knowledge, attitudes and practices about pharmacovigilance in India: a systematic review and meta-analysis,” Plo S one, vol. 11, no. 3, article e0152221, 2016.
57. A. D. Hailu and S. A. Mohammed, “Adverse drug reaction reporting in Ethiopia: systematic review,” Bio Med Research International, vol. 2020, article 8569314, pp. 1–12, 2020.
58. Morrison Asiamah, “Spontaneous reporting of adverse drug reaction among health professionals in Ghana”, Pub Med Central ., Published online 2022 Jan 20.
59. S. Palaian, M. I. Ibrahim, and P. Mishra, “Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal,” Pharmacy practice, vol. 9, no. 4, pp. 228–235, 2011.
60. E. Hristov, S. Ognyanov, T. Deliyski et al., “Effect of pharmacist involvement on patient reporting of adverse drug reactions in Bulgaria,” Journal of Advanced Research in Pharmaceutical Sciences and Pharmacology Interventions, vol. 2, no. 2, pp. 1– 6, 2019.
61. H. Rehan, R. K. Sah, and D. Chopra, “Comparison of knowledge, attitude and practices of resident doctors and nurses on adverse drug reaction monitoring and reporting in a tertiary
62. care hospital,” Indian journal of pharmacology., vol. 44, no. 6, pp. 699–703, 2012.
63. J. Liu, Z. Zhou, S. Yang et al., “Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China,” International Journal of Clinical Pharmacy, vol. 37, no. 3, pp. 457–464, 2015.
64. S. Gautron, J. Wentzell, S. Kanji, T. Nguyen, D. Kobewka, and D. E. Mac, “Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting,” The Canadian journal of hospital pharmacy, vol. 71, no. 5, pp. 316–323, 2018.
65. A. De Angelis, S. Colaceci, A. Giusti, E. Vellone, and R. Alvaro, “Factors that condition the spontaneous reporting of adverse drug reactions among nurses: an integrative review,” Journal of nursing management., vol. 24, no. 2, pp. 151–163, 2016.
66. A. R. Abubakar, N. B. Simbak, and M. Haque, “A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors,” Journal of Applied Pharmaceutical Science., vol. 4, no. 10, pp. 117–127, 2014.
67. M. Vaismoradi, S. Jordan, and M. Kangasniemi, “Patient participation in patient safety and nursing input–a systematic review,” Journal of clinical nursing., vol. 24, no. 5-6, pp. 627– 639, 2015.
68. F. R. Varallo, S. O. P. Guimarães, S. A. R. Abjaude, and P. C. Mastroianni, “Causes for the underreporting of adverse drug events by health professionals: a systematic review,” Revista da Escola de Enfermagem da USP, vol. 48, no. 4, pp. 739–747, 2014.
69. T. Dilles, R. V. Stichele, B. Van Rompaey, L. Van Bortel, and M. Elseviers, “Nurses’ and Doctor’s practices in pharmacotherapy and their association with educational level,” Journal of advanced nursing., vol. 66, no. 5, pp. 1072–1079, 2010.
70. G. Cereza, A. Agustí, C. Pedrós et al., “Effect of an intervention on the features of adverse drug reactions spontaneously reported in a hospital,” European journal of clinical pharmacology., vol. 66, no. 9, pp. 937–945, 2010.
71. D. Stewart, K. Mac Lure, V. Paudyal, C. Hughes, M. Courtenay, and J. McLay, “Non-medical prescribers and pharmacovigilance: participation, competence and future needs,” International Journal of Clinical Pharmacy, vol. 35, no. 2, pp. 268–274, 2013.
72. M. Bäckström, E. Ekman, and T. Mjörndal, “Adverse drug reaction reporting by nurses in Sweden,” European journal of clinical pharmacology., vol. 63, no. 6, pp. 613–618, 2007.
73. M. E. Ndosi and R. Newell, “Nurses’ and Doctor’s knowledge of pharmacology behind drugs they commonly administer,” Journal of clinical nursing., vol. 18, no. 4, pp. 570–580, 2009.
74. M. Vaismoradi, S. Jordan, F. Vizcaya-Moreno, I. Friedl, and M. Glarcher, “PRN medicines optimization and nurse education,” Pharmacy., vol. 8, no. 4, p. 201, 2020.
75. A. Mardani, P. Griffiths, and M. Vaismoradi, “The role of the nurse in the management of medicines during transitional care: a systematic review,” Journal of multidisciplinary healthcare, vol. Volume 13, pp. 1347–1361, 2020.
76. Lavina Prashar, “Inadequate Knowledge and Practice of Pharmacovigilance affecting Adverse Drug Reaction Reporting by Health Professionals in Private Healthcare Facilities in Lusaka, Zambia,” ResearchGate, March 2020
77. C. K. Desai, G. Iyer, J. Panchal, S. Shah, and R. Dikshit, “An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital,” Perspectives in Clinical research, vol. 2, no. 4, pp. 129–136, 2011.
78. M. Bisht, S. Singh, and D. Dhasmana, “Effect of educational intervention on adverse drug reporting by physicians: a cross-sectional study,” International Scholarly Research Notices., vol. 2014, article 259476, pp. 1–8, 2014.
79. L. Hazell and S. A. Shakir, “Under-reporting of adverse drug reactions,” Drug safety, vol. 29, no. 5, pp. 385–396, 2006.
80. E. Lopez-Gonzalez, M. T. Herdeiro, and A. Figueiras, “Determinants of under-reporting of adverse drug reactions,” Drug safety., vol. 32, no. 1, pp. 19–31, 2009.
81. C. Palleria, C. Leporini, S. Chimirri et al., “Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two “challenging” case reports,” Journal of pharmacology & pharmacotherapeutics., vol. 4, Suppl 1, pp. S66–S72, 2013.
82. Dorkasi L. Mwakawanga, “Pharmacovigilance and Adverse Drug Reactions Reporting: Healthcare Providers' Experiences from Southern Highland Tanzania,” Adv Pharmacol Pharm Sci. 2023.
Article Sidebar
Published
Oct 11, 2022
Article Details
How to Cite
Dr.naif shujaa Alotaibi, Saif Salem Al Salem, Ali Mohammed Alhudaif, Abdullah Ibrahim Ayat Al-Anazi, Jalwi Jamaan mahammed alqahtani, Fisal Jeza Ginan Almutairi, Omar Bashir Ma'ad Al-Mutairi, Sultan Mohammad Ibrahim AlOrf, & Sultan mujeri alruqi. (2022). A SYSTEMATIC REVIEW OF NURSES’ AND DOCTOR’S KNOWLEDGE, ATTITUDES, AND PRACTICE IN CONNECTION TO PHARMACOVIGILANCE AND ADVERSE DRUG REACTION REPORTING. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 3374-3388. https://doi.org/10.53555/jptcp.v29i04.5886
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Dr.naif shujaa Alotaibi
Bariatric surgery, Dammam medical complex Dammam
Saif Salem Al Salem
Surgical technician, King Khaled Hospital in Najran Najran
Ali Mohammed Alhudaif
Dermatology, al diriyah hospital Al Riyadh
Abdullah Ibrahim Ayat Al-Anazi
Pharmacist, Muhammadiyah PHC, Hafar Al-Batin
Jalwi Jamaan mahammed alqahtani
Pharmacist, Khurma hospital Altaif
Fisal Jeza Ginan Almutairi
Pharmacist, Al-Artawiyah General Hospital Al-Artawiyah
Omar Bashir Ma'ad Al-Mutairi
X-ray teachnation, Alhusso General Hospital Madina
Sultan Mohammad Ibrahim AlOrf
Radiology technician, Riyadh
Sultan mujeri alruqi
Al-Ghadeer Primary healthcare center, Administration hospitals King Fahad Hospital Jeddah
How to Cite
Dr.naif shujaa Alotaibi, Saif Salem Al Salem, Ali Mohammed Alhudaif, Abdullah Ibrahim Ayat Al-Anazi, Jalwi Jamaan mahammed alqahtani, Fisal Jeza Ginan Almutairi, Omar Bashir Ma'ad Al-Mutairi, Sultan Mohammad Ibrahim AlOrf, & Sultan mujeri alruqi. (2022). A SYSTEMATIC REVIEW OF NURSES’ AND DOCTOR’S KNOWLEDGE, ATTITUDES, AND PRACTICE IN CONNECTION TO PHARMACOVIGILANCE AND ADVERSE DRUG REACTION REPORTING. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 3374-3388. https://doi.org/10.53555/jptcp.v29i04.5886